Emerging Stocks Down Under 24 August 2021: Prescient Therapeutics, COSOL, Cardiex

Emerging Stocks Down Under: Prescient Therapeutics, COSOL, Cardiex

Prescient Therapeutics: Making headway in cancer treatment

In today’s edition of Emerging Stocks Down Under, Prescient Therapeutics is a Melbourne-based clinical-stage oncology company currently developing and trialling drugs for the treatment of a variety of cancers. It is currently in Phase-II trials for its lead candidate PTX-200, which has potential to be used for the treatment of HER2-negative breast cancer, amongst other things. Apart from this, the company has a pipeline that targets relapsed and refractory AML, ovarian cancer and cancers with Ras and RhoA mutations.


Also in today’s edition, a look at asset-intensive industry software developer COSOL (ASX: COS) and medical device manufacturer Cardiex (ASX: CDX).


Click here to read the previous edition of Emerging Stocks Down Under published 17 August 2021

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.